Enzyme replacement therapy in a mouse model of aspartylglycosaminuria.
Dunder U, Kaartinen V, Valtonen P, Väänänen E, Kosma VM, Heisterkamp N, Groffen J, Mononen I.
Dunder U, et al. Among authors: mononen i.
FASEB J. 2000 Feb;14(2):361-7. doi: 10.1096/fasebj.14.2.361.
FASEB J. 2000.
PMID: 10657992
In the current study, recombinant human AGA administered i.v. to adult AGU mice disappeared from the systemic circulation of the animals in two phases predominantly into non-neuronal tissues, which were rapidly cleared from storage compound aspartylglucosamine. ...-Dunder, …
In the current study, recombinant human AGA administered i.v. to adult AGU mice disappeared from the systemic circulation of the anim …